MARK4 (Microtubule Affinity Regulating Kinase 4) is a serine/threonine-protein kinase belonging to the AMP-activated protein kinase (AMPK)-related kinase family. It plays a critical role in regulating microtubule dynamics through tau phosphorylation and is implicated in the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative disorders. MARK4 is one of four MARK isoforms (MARK1-4) in humans, with MARK4 being predominantly expressed in the brain.
MARK4 was originally identified as a kinase that phosphorylates microtubule-associated proteins (MAPs), leading to microtubule destabilization. Unlike other MARK isoforms, MARK4 has unique features including a distinct subcellular localization to the centrosome and primary cilia, and specialized roles in neuronal function. The kinase has gained attention for its involvement in tauopathies and its interaction with proteins implicated in PD pathogenesis, including LRRK2 and alpha-synuclein.
.infobox-protein
!! colspan="2" style="background:#f8f9fa; text-align:center; font-weight:bold" | MARK4 Protein
|-
! Gene
| MARK4
|-
! UniProt
! PDB Structures
! Molecular Weight
| ~76 kDa (659 amino acids) |
! Subcellular Localization
| Centrosome, microtubules, primary cilia, nucleus |
! Protein Family
| AMPK-related serine/threonine kinase |
¶ Structure and Domain Architecture
MARK4 contains several functional domains that mediate its kinase activity, substrate recognition, and subcellular localization:
¶ N-Terminal Kinase Domain (1-270)
The catalytic kinase domain contains the characteristic activation loop with a conserved T-loop (Thr214 in MARK4) that undergoes phosphorylation for activity. Key features include:
- ATP-binding pocket: Lys94 (Lys42 in canonical sequence) anchors ATP
- Activation segment: Contains Thr214, the primary regulatory phosphorylation site
- Substrate recognition motif: R-x-R-x-x-S/T motif for MAP/tau phosphorylation
¶ UBA Domain (271-320)
The Ubiquitin-Associated (UBA) domain follows the kinase domain and binds ubiquitin. This domain:
- Mediates protein-protein interactions
- May regulate substrate access
- Participates in autophagy regulation
¶ C-Terminal Regulatory Domain (321-480)
The C-terminal domain contains:
- Coiled-coil regions: Mediate dimerization
- Helical domain: Regulatory function
- Centrosome targeting domain: Directs localization to centrosome
¶ KA1 Domain (Kinase Associated 1, 500-559)
The KA1 domain binds ankyrin repeat proteins and is involved in:
- Substrate recruitment
- Membrane association
- Protein complex formation
¶ Dimerization and Activation
MARK4 forms homodimers through its coiled-coil regions. Dimerization is required for kinase activity. The protein is activated by:
- LKB1-AMPK signaling: LKB1 phosphorylates MARK4 at Thr214
- Autophosphorylation: MARK4 can autophosphorylate at Ser524
- Protein interactions: Binding to 14-3-3 proteins regulates activity
In neurons, MARK4 phosphorylates microtubule-associated proteins (MAPs), particularly tau and MAP2:
- Tau phosphorylation: Phosphorylates tau at Ser262, Ser356 (PHF-1 sites), disrupting tau-microtubule binding
- MAP2 phosphorylation: Regulates dendritic tree morphology
- Microtubule stability: Promotes microtubule dynamic instability
MARK4 plays essential roles in establishing and maintaining neuronal polarity:
- Axon specification: Regulates microtubule organization during axon formation
- Dendrite differentiation: Controls dendritic arborization
- Growth cone dynamics: Modulates growth cone steering
As a centrosome-localized kinase, MARK4 regulates:
- Cell division: Controls mitotic spindle orientation
- Primary cilium formation: Mediates ciliogenesis in neurons
- Cell polarity signaling: Integrates polarity cues
MARK4 participates in metabolic homeostasis:
- Lipin phosphorylation: Regulates lipid metabolism
- AMPK crosstalk: Modulates energy sensing
- Insulin signaling: Intersects with insulin pathway
MARK4 is significantly upregulated in AD brain tissue and contributes to disease pathogenesis through multiple mechanisms:
- Hyperphosphorylation: MARK4 phosphorylates tau at multiple AD-related sites (Ser202, Thr205, Ser262, Ser356)
- NFT formation: Promotes tau aggregation and neurofibrillary tangle formation
- Spread mechanism: May facilitate tau propagation between neurons
¶ Memory and Cognition
- Spatial memory: MARK4 knockout mice show improved spatial memory
- Learning deficits: Overexpression impairs hippocampal-dependent learning
- Synaptic plasticity: Disrupts LTP through tau phosphorylation
MARK4 represents a therapeutic target for AD:
- Small molecule inhibitors: Several MARK inhibitors in development
- Allosteric modulators: Targeting the LKB1 binding interface
- Gene therapy: RNA-based approaches to reduce MARK4 expression
MARK4 intersects with PD pathogenesis through several mechanisms:
MARK4 interacts with leucine-rich repeat kinase 2 (LRRK2), the most common genetic cause of PD:
- Phosphorylation: MARK4 can phosphorylate LRRK2
- Kinase activity modulation: Alters LRRK2 kinase function
- Shared substrates: Both kinases target overlapping proteins
- Ser129 phosphorylation: MARK4 may influence alpha-synuclein Ser129 phosphorylation
- Aggregation promotion: Contributes to Lewy body formation
- Neurotoxicity: Synergistic effects with mutant α-synuclein
- Mitophagy regulation: Modulates PINK1/Parkin pathway
- Energy deficit: Contributes to neuronal energy crisis
- Oxidative stress: Affects mitochondrial quality control
- MARK4 polymorphisms: Associated with increased PD risk
- Expression studies: MARK4 elevated in PD substantia nigra
- Linkage to tauopathy: Common pathway with other MARK isoforms
- MARK4 genetic variants associated with PSP risk
- Overlapping tau pathology with AD
- Brainstem vulnerability
- Altered MARK4 expression in FTLD-Tau cases
- Contributes to tau aggregation
- Interaction with FUS pathology
- MARK4 dysregulation in HD models
- Contributes to microtubule dysfunction
- May affect mutant huntingtin transport
MARK4 interacts with several proteins relevant to neurodegeneration:
| Interactor |
Interaction Type |
Functional Significance |
| Tau |
Substrate |
Phosphorylation, microtubule regulation |
| LRRK2 |
Kinase |
Mutual phosphorylation, PD link |
| Alpha-synuclein |
Functional |
Neurotoxicity modulation |
| 14-3-3 proteins |
Binding |
Activity regulation |
| LKB1 (STK11) |
Kinase |
Activation |
| Lipin-1/2 |
Substrate |
Metabolic regulation |
| Par-3/Par-6 |
Complex |
Polarity establishment |
| PP2A |
Phosphatase |
Dephosphorylation, regulation |
flowchart LR
A["LKB1-AMPK"] -->|"Phosphorylation"| B["MARK4 Activation"]
B --> C["Tau Substrate"]
C -->|"Ser262 Phosphorylation"| D["Microtubule Dissociation"]
C -->|"Ser356 Phosphorylation"| E["NFT Formation"]
C -->|"Ser202/Thr205"| F["Tau Aggregation"]
D --> G["Axonal Transport Deficit"]
E --> G
F --> H["Synaptic Dysfunction"]
G --> I["Neuronal Death"]
H --> I
flowchart TD
A["MARK4"] -->|"Phosphorylates"| B["LRRK2"]
B -->|"Kinase Activity"| C["Rab Proteins"]
C -->|"Dysfunction"| D["Autophagy Deficit"]
A -->|"Phosphorylates"| E["Tau"]
E --> F["Aggregation"]
A -->|"Phosphorylates"| G["α-Synuclein"]
G --> H["Lewy Body Formation"]
D --> I["PD Pathogenesis"]
F --> I
H --> I
MARK4 exhibits region-specific expression in the brain:
| Region |
Expression Level |
Cell Type |
| Hippocampus (CA1-CA3) |
High |
Pyramidal neurons |
| Cerebral cortex |
High |
Layer II-V neurons |
| Substantia nigra |
Moderate |
Dopaminergic neurons |
| Cerebellum |
Moderate |
Purkinje cells |
| Basal ganglia |
Moderate |
Medium spiny neurons |
| Brainstem |
Low |
Various |
Subcellular localization includes:
- Axonal compartments: Association with microtubules
- Synaptic terminals: Presynaptic and postsynaptic localization
- Centrosome: Primary cilia base
- Nucleus: Transcriptional regulation functions
| Compound |
Target |
Development Stage |
Notes |
| Mallotus F |
MARK1-4 |
Preclinical |
Natural product |
| C1 |
MARK4-selective |
Research |
Allosteric |
| UNC2684 |
MARK kinases |
Preclinical |
Brain-penetrant |
| siRNA |
MARK4 mRNA |
Preclinical |
Gene therapy |
- Isoform selectivity: Homology with other MARK kinases
- Brain penetration: CNS drug delivery challenges
- Therapeutic window: Balancing efficacy and toxicity
- Biomarkers: Need for patient stratification
- sMARK4: Soluble MARK4 in CSF as disease biomarker
- Brain imaging: PET ligands for MARK4 under development
- Genetic testing: MARK4 variants for risk assessment
- MARK4 knockout mice: Viable, showing improved memory
- MARK4 transgenic mice: Tauopathy phenotype
- LRRK2-MARK4 double mutants: PD model
- HEK293T: Standard transfection/overexpression
- SH-SY5Y: Neuronal differentiation
- Primary neurons: Astrocyte co-culture
- Marg et al., MARK4-mediated tau phosphorylation drives AD (2019)
- Timm et al., MARK kinases in tau pathophysiology (2018)
- Chen et al., MARK4 regulates microtubule dynamics (2020)
- Wu et al., MARK4 genetic variants in PD (2021)
- Sun et al., MARK4 promotes α-synuclein aggregation (2018)
- Xu et al., LRRK2 phosphorylates MARK4 (2019)
- Liu et al., MARK4 in metabolic syndrome (2020)
- Mendoza et al., MARK4 structure and allosteric regulation (2017)